Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peposertib (M3814) and MEC in Relapsed or Refractory Acute Myeloid Leukemia
NCT03983824Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2020
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of peposertib in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Primary endpoint: Incidence of adverse events up to 5 years. Started May 2020; status: active, not recruiting.
02
Drugs
peposertib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03983824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03983824.